Neoborocillin Throat Pain 16 Lozenges Without Sugar
€9.90
Tax included
Brand
Minsan
035760040
100% secure payments
Sorry, no items left.
WARNINGS
At the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not in itself involve any harm to the patient, as these doses are far lower than those commonly used in treatments with flurbiprofen systemically. The mouthwash and spray for oral mucosa contain methyl parahydroxybenzoate and propyl parahydroxybenzoate as preservatives: they can cause allergic reactions, sometimes of a delayed type; they contain a small amount of ethyl alcohol less than 100 mg per dose. Due to the presence of sorbitol, patients with rare hereditary problems of fructose intolerance should not take this medicine. In patients with renal, cardiac or hepatic insufficiency the medicinal product should be used with caution. It is recommended not to combine the medicine with NSAIDs. The use, especially if prolonged, of the product can give rise to sensitization phenomena or local irritation; in such cases it is necessary to interrupt the treatment and consult the doctor to establish, if necessary, a suitable therapy. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor.
PHARMACOTHERAPEUTIC CATEGORY
Dental.
STORAGE
Mouthwash and spray for oral mucosa: no particular storage conditions. Tablets: Store at a temperature not exceeding 25 degrees C.
CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity '(asthma, bronchospasm, urticaria or allergic type) towards flurbiprofen or any of the excipients, and towards acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs); third trimester of pregnancy; administration of flurbiprofen is not recommended in nursing mothers; do not use in patients who have a peptic ulcer or who have had it in the past; do not administer the tablets to children under the age of 12.
NAME
NEO BOROCILLIN THROAT PAIN
EXCIPIENTS
Mouthwash in bottle and spray for oral mucosa: glycerol, ethanol 96%, non crystallizable liquid sorbitol, hydrogenated castor oil-40 polyoxyethylenate, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, essential oil trirected mint, patent blue V (E 131), anhydrous citric acid, purified water. Mouthwash in single-dose containers: glycerol, ethanol 96%, non-crystallizable liquid sorbitol, hydrogenated castor oil-40 polyoxyethylenate, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint flavor, patent blue V (E 131), anhydrous citric acid , purified water. Tablets: glycerol dibeenate, acesulfame potassium, balsamic mint flavor, mannitol, copovidone.
SIDE EFFECTS
The use of the medicine, especially if prolonged, can give rise to sensitization phenomena or local irritation; in such cases it is necessary to interrupt the treatment and institute, if necessary, a suitable therapy. The following undesirable effects have been reported, particularly after the administration of higher doses systemically. Blood and lymphatic system disorders: thrombocytopenia, aplastic anemia and agranulocytosis. Immune system disorders: anaphylaxis, angioedema, allergic reaction. Nervous system disorders: dizziness, cerebrovascular accidents, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, dizziness, discomfort, fatigue and somnolence. Ear and labyrinth disorders: tinnitus. Respiratory, thoracic and mediastinal disorders: reactivity of the respiratory tract (asthma, bronchospasm and dyspnoea). Gastrointestinal disorders: the most commonly observed adverse events are gastrointestinal in nature. Nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease have been reported following administration of flurbiprofen. Gastritis, peptic ulcer, perforation and ulcer haemorrhage were observed less frequently. Skin and subcutaneous tissue disorders: skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatosis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). Renal and urinary disorders: nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported.
PREGNANCY AND BREASTFEEDING
During the first and second trimester of pregnancy, flurbiprofen should not be administered except in strictly necessary cases. The drug administered during pregnancy can delay the onset of labor and increase its duration. Administration of flurbiprofen is not recommended in nursing mothers.
INDICATIONS
The oral mucosa mouthwash / spray drug is used in the symptomatic treatment of irritative-inflammatory states also associated with oropharyngeal pain (eg gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. The tablets are used in the symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (eg gingivitis, stomatitis, pharyngitis).
INTERACTIONS
However, inform your doctor if you are taking other medications. As demonstrated in some clinical studies, flurbiprofen may occasionally reduce the diuretic activity of furosemide. Furthermore, flurbiprofen may occasionally interfere with the action of anticoagulant drugs. However, no interaction of flurbiprofen with digoxin, tolbutamide and antacids has been demonstrated.
DOSAGE
Mouthwash: the recommended dose is 2-3 rinses or gargles per day with 10 ml of mouthwash (using the appropriate measuring cup or a single-dose container), diluted in half a glass of water or pure. Oral mucosal spray: the recommended dose is 2 sprays 3 times a day addressed directly to the affected area; each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active principle. >> Pads. Adults and children over 12 years: 1 tablet to be dissolved slowly in the mouth every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. Do not administer to children under the age of 12. Dosage changes are not necessary for the elderly.
ACTIVE PRINCIPLES
Flurbiprofen.
At the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not in itself involve any harm to the patient, as these doses are far lower than those commonly used in treatments with flurbiprofen systemically. The mouthwash and spray for oral mucosa contain methyl parahydroxybenzoate and propyl parahydroxybenzoate as preservatives: they can cause allergic reactions, sometimes of a delayed type; they contain a small amount of ethyl alcohol less than 100 mg per dose. Due to the presence of sorbitol, patients with rare hereditary problems of fructose intolerance should not take this medicine. In patients with renal, cardiac or hepatic insufficiency the medicinal product should be used with caution. It is recommended not to combine the medicine with NSAIDs. The use, especially if prolonged, of the product can give rise to sensitization phenomena or local irritation; in such cases it is necessary to interrupt the treatment and consult the doctor to establish, if necessary, a suitable therapy. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor.
PHARMACOTHERAPEUTIC CATEGORY
Dental.
STORAGE
Mouthwash and spray for oral mucosa: no particular storage conditions. Tablets: Store at a temperature not exceeding 25 degrees C.
CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity '(asthma, bronchospasm, urticaria or allergic type) towards flurbiprofen or any of the excipients, and towards acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs); third trimester of pregnancy; administration of flurbiprofen is not recommended in nursing mothers; do not use in patients who have a peptic ulcer or who have had it in the past; do not administer the tablets to children under the age of 12.
NAME
NEO BOROCILLIN THROAT PAIN
EXCIPIENTS
Mouthwash in bottle and spray for oral mucosa: glycerol, ethanol 96%, non crystallizable liquid sorbitol, hydrogenated castor oil-40 polyoxyethylenate, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, essential oil trirected mint, patent blue V (E 131), anhydrous citric acid, purified water. Mouthwash in single-dose containers: glycerol, ethanol 96%, non-crystallizable liquid sorbitol, hydrogenated castor oil-40 polyoxyethylenate, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint flavor, patent blue V (E 131), anhydrous citric acid , purified water. Tablets: glycerol dibeenate, acesulfame potassium, balsamic mint flavor, mannitol, copovidone.
SIDE EFFECTS
The use of the medicine, especially if prolonged, can give rise to sensitization phenomena or local irritation; in such cases it is necessary to interrupt the treatment and institute, if necessary, a suitable therapy. The following undesirable effects have been reported, particularly after the administration of higher doses systemically. Blood and lymphatic system disorders: thrombocytopenia, aplastic anemia and agranulocytosis. Immune system disorders: anaphylaxis, angioedema, allergic reaction. Nervous system disorders: dizziness, cerebrovascular accidents, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, dizziness, discomfort, fatigue and somnolence. Ear and labyrinth disorders: tinnitus. Respiratory, thoracic and mediastinal disorders: reactivity of the respiratory tract (asthma, bronchospasm and dyspnoea). Gastrointestinal disorders: the most commonly observed adverse events are gastrointestinal in nature. Nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease have been reported following administration of flurbiprofen. Gastritis, peptic ulcer, perforation and ulcer haemorrhage were observed less frequently. Skin and subcutaneous tissue disorders: skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatosis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). Renal and urinary disorders: nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported.
PREGNANCY AND BREASTFEEDING
During the first and second trimester of pregnancy, flurbiprofen should not be administered except in strictly necessary cases. The drug administered during pregnancy can delay the onset of labor and increase its duration. Administration of flurbiprofen is not recommended in nursing mothers.
INDICATIONS
The oral mucosa mouthwash / spray drug is used in the symptomatic treatment of irritative-inflammatory states also associated with oropharyngeal pain (eg gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. The tablets are used in the symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (eg gingivitis, stomatitis, pharyngitis).
INTERACTIONS
However, inform your doctor if you are taking other medications. As demonstrated in some clinical studies, flurbiprofen may occasionally reduce the diuretic activity of furosemide. Furthermore, flurbiprofen may occasionally interfere with the action of anticoagulant drugs. However, no interaction of flurbiprofen with digoxin, tolbutamide and antacids has been demonstrated.
DOSAGE
Mouthwash: the recommended dose is 2-3 rinses or gargles per day with 10 ml of mouthwash (using the appropriate measuring cup or a single-dose container), diluted in half a glass of water or pure. Oral mucosal spray: the recommended dose is 2 sprays 3 times a day addressed directly to the affected area; each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active principle. >> Pads. Adults and children over 12 years: 1 tablet to be dissolved slowly in the mouth every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. Do not administer to children under the age of 12. Dosage changes are not necessary for the elderly.
ACTIVE PRINCIPLES
Flurbiprofen.
chat
Comments (0)
No customer reviews for the moment.
